Funding maturity profile Nordea Direct Boligkreditt covered bonds Nordea Direct Boligkreditt provides residential mortgage loans. The lending portfolio is primarily financed by the issuance of covered bonds. Read more Nordea Eiendomskreditt covered bonds Nordea Hypotek covered bonds Nordea Kredit covered bonds Nordea Kredit grants mortgage lending secured by residential, commercial, agricultural or industrial properties in Denmark. All lending is 100% match funded through the issuing of covered mortgage bonds and mortgage bonds. Read more Nordea Mortgage Bank covered bonds Nordea Mortgage Bank is licensed by the Finnish Financial Supervisory Authority to issue covered bonds. Read more Green bonds Promoting businesses and innovations with sustainable solutions of energy and infrastructure is a priority in our investment and lending policies and guidelines.
Investegate announcements from Suominen Corporation, Listing Prospectus for Suominen Corporation’s EUR 50 million bond available; listing application submitted
Suominen Corporation’s Stock Exchange Release on June 11, 2021 at 4:00 p.m. (EEST) NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. Suominen Corporation announced its decision to issue a senior unsecured bond of EUR 50 million on June 4, 2021. The bond will
Nanoform raises its mid-term business targets for 2025
Nanoform
Insider information
Nanoform raises its mid-term business targets for 2025
Helsinki, Finland – Nanoform Finland Plc (“Nanoform”), an innovative nanoparticle medicine enabling company, today announced its raised mid-term business targets for 2025. The new targets are as follows:
To nanoform annually at least 70 new active pharmaceutical ingredients, or ‘APIs’ (40% increase from the previous target of at least 50 new APIs annually)
To have in place 35 operating production lines, of which 7 to 14 are expected to be GMP compliant (40% increase from the previous target of 25 operating lines, of which 5-10 are GMP compliant)
To have 200-250 employees (0-25% increase from the previous target of ~200)
Nanoform Interim Report January – March (Q1) 2021
Nanoform
Company Announcement
Nanoform Interim Report January – March (Q1) 2021
Strong momentum continues: three new non-GMP lines commissioned, four new clients signed, and six new customer PoC projects commenced. In addition, positive results from first clinical study announced, two near-term business targets achieved (“First Biologics PoC in 2021” and “at least three new non-GMP lines in 2021”), next generation STARMAP
® launched, EUR 40 million successfully raised and commercial teams in the US and the UK further strengthened.
1-3/2021 key financials
- Revenue EUR 278 thousand, growth + 85%, stemming from 14 different customer projects (EUR 150 thousand, 6 customer projects in 1-3/2020).
- The gross profit and gross margin improved to EUR 243 thousand and 88%, respectively (EUR 103 thousand, 68%).